Latest heart attack diagnosis guidance
The
newest international standard is the
Fifth Universal Definition of Myocardial Infarction, 2026, issued jointly by the ESC, ACC, AHA, and World Heart Federation. It replaces the 2018 definition. The
ESC 2026 statement emphasizes sex-specific troponin thresholds, serial testing, accelerated high-sensitivity troponin pathways, and imaging to establish the cause.
The 2025 ACC/AHA/ACEP/NAEMSP/SCAI Acute Coronary Syndromes guideline remains the newest major US management guideline for suspected ACS, including STEMI, NSTEMI, and unstable angina. It supersedes earlier separate US STEMI and NSTEMI guidelines. [Practice Guideline . Tier 6 . 2025] Rao et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for Acute Coronary Syndromes. Circulation. PMID: 40014670. An erratum is listed for this article, PMID: 41212941.
Core diagnostic approach
A heart attack, or myocardial infarction (MI), requires both:
-
Acute myocardial injury
- Cardiac troponin above the assay's 99th-percentile upper reference limit, and
- A significant rise and/or fall on serial blood testing.
-
Clinical evidence that acute ischemia caused the injury, such as at least one of:
- Symptoms compatible with ischemia, for example chest pressure, breathlessness, sweating, nausea, jaw/arm/back discomfort
- New ischemic ECG changes
- Development of pathological Q waves
- Imaging showing new loss of viable heart muscle or a new regional wall-motion abnormality
- Coronary thrombus identified by angiography or autopsy
This distinction matters: a raised troponin alone is myocardial injury, not automatically a heart attack. Kidney disease, severe infection, fast arrhythmia, pulmonary embolism, heart failure, and other conditions can raise troponin.
Tests recommended immediately for suspected heart attack
| Test | Role |
|---|
| 12-lead ECG | Obtain immediately and repeat if symptoms continue or the first ECG is non-diagnostic. Identifies ST-elevation and other ischemic or occlusion patterns. |
| High-sensitivity cardiac troponin, serial tests | Preferred biomarker. Use a validated local 0/1-hour, 0/2-hour, or other accelerated pathway, not a single isolated result. |
| Clinical assessment | Symptoms, onset time, risk factors, examination, blood pressure, pulse, oxygen saturation, and alternative diagnoses. |
| Echocardiography | Detects new regional wall-motion abnormality, reduced ventricular function, and mechanical complications. It is especially useful when ECG or troponin findings are uncertain. |
| Coronary angiography | Defines coronary anatomy and identifies a culprit blockage. It is urgent when STEMI or an occlusion pattern is suspected. |
| Coronary CT angiography or cardiac MRI | Selective tests when the diagnosis or cause remains unclear. Cardiac MRI can differentiate infarction from myocarditis, Takotsubo syndrome, and other myocardial injury. |
What is new or emphasized in 2026
- Sex-specific troponin thresholds are incorporated to reduce underdiagnosis, especially in women.
- High-sensitivity troponin accelerated diagnostic pathways are formally emphasized.
- Imaging is encouraged to determine the underlying cause of MI.
- MI is now classified clinically as:
- Primary MI: spontaneous coronary event, commonly plaque disruption with thrombosis.
- Secondary MI: oxygen supply-demand imbalance, without primary acute coronary thrombosis.
- Procedure-related MI.
- The updated definition also provides clearer criteria for silent or unrecognized MI and reframes MINOCA as a working diagnostic category that requires further evaluation. The ACC summary of the 2026 update describes these changes.
The
2023 ESC ACS guideline remains a major ACS care reference internationally, but the 2026 Universal Definition is the latest authority specifically for defining and diagnosing MI.
If chest pain, pressure, acute breathlessness, cold sweating, fainting, or pain radiating to the jaw, back, or arm is occurring now, seek emergency help immediately. Diagnosis must not be delayed for outpatient testing.